Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Non-Small Cell Lung Cancer News

News
ASCO Living Guideline Updated for Stage IV NSCLC
08/16/2022

Yvette C Terrie

Yvette C Terrie
Researchers provided evidence-based recommendations updating the 2020 ASCO and Ontario Health (Cancer Care Ontario) guideline on systemic therapy for patients with stage IV non–small-cell lung cancer without driver alterations.
Researchers provided evidence-based recommendations updating the 2020 ASCO and Ontario Health (Cancer Care Ontario) guideline on systemic therapy for patients with stage IV non–small-cell lung cancer without driver alterations.
Researchers provided...
08/16/2022
Journal of Clinical Pathways
News
Progression-Free Survival Associated With Alectinib vs Crizotinib Among Patients With Advanced NSCLC
06/09/2022

Ellen Kurek

Ellen Kurek
Researchers in China studied 168 patients over three 3 to determine the benefits of tyrosine kinase inhibitor therapy in patient s with ALK-positive locally advanced or metastatic NSCLC.
Researchers in China studied 168 patients over three 3 to determine the benefits of tyrosine kinase inhibitor therapy in patient s with ALK-positive locally advanced or metastatic NSCLC.
Researchers in China studied 168...
06/09/2022
Journal of Clinical Pathways

Advertisement

News
Artificial Intelligence-Powered Spatial Analysis of TILs Predicts Treatment Outcomes With ICIs in NSCLC
05/16/2022

Ellen Kurek

Ellen Kurek
Researchers developed a whole-slide image analyzer powered by artificial intelligence that could detect three immune phenotypes that correlated with treatment outcomes to immune checkpoint inhibitors among patients with NSCLC.
Researchers developed a whole-slide image analyzer powered by artificial intelligence that could detect three immune phenotypes that correlated with treatment outcomes to immune checkpoint inhibitors among patients with NSCLC.
Researchers developed a...
05/16/2022
Journal of Clinical Pathways
News
Consortium Explores Racial Differences in Treatment and Toxicity in Patients With Non-Small Cell Lung Cancer Receiving Definitive Thoracic Radiotherapy
04/20/2022

Ellen Kurek

Ellen Kurek
Black patients reported significantly greater general pain both before the initiation of radiation therapy and at the end of radiation therapy, according to an analysis of racial differences in thoracic radiation treatment and related...
Black patients reported significantly greater general pain both before the initiation of radiation therapy and at the end of radiation therapy, according to an analysis of racial differences in thoracic radiation treatment and related...
Black patients reported...
04/20/2022
Journal of Clinical Pathways
News
Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among US Patients With Early-Stage NSCLC
04/05/2022

Marta Rybczynski

Marta Rybczynski
Among participants in a screening protocol for adjuvant clinical trials for resected early-stage NSCLC, only about half underwent adequate lymph node dissection and received adjuvant chemotherapy, despite guideline indications.
Among participants in a screening protocol for adjuvant clinical trials for resected early-stage NSCLC, only about half underwent adequate lymph node dissection and received adjuvant chemotherapy, despite guideline indications.
Among participants in a...
04/05/2022
Journal of Clinical Pathways

Advertisement

News
Real-World Effectiveness of Immunotherapy Among Patients With Pre-treated, Advanced NSCLC
04/05/2022

Marta Rybczynski

Marta Rybczynski
Study findings shed light on survival outcomes among vulnerable groups of pre-treated patients with advanced NSCLC receiving immunotherapy, who are often excluded from real-world clinical trials.
Study findings shed light on survival outcomes among vulnerable groups of pre-treated patients with advanced NSCLC receiving immunotherapy, who are often excluded from real-world clinical trials.
Study findings shed light on...
04/05/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Adjuvant Osimertinib for Resected EGFR-Mutant NSCLC
04/01/2022

Janelle Bradley

Janelle Bradley
Findings from a cost-effectiveness analysis demonstrate that there is significant cost associated with the use of 3 years of adjuvant osimertinib for patients with resected EGFR-mutant NSCLC.
Findings from a cost-effectiveness analysis demonstrate that there is significant cost associated with the use of 3 years of adjuvant osimertinib for patients with resected EGFR-mutant NSCLC.
Findings from a...
04/01/2022
Journal of Clinical Pathways
News
Biomarker Testing Rates and Turnaround Times for Patients With NSCLC Receiving First-Line Therapy in The US Oncology Network
04/01/2022

Janelle Bradley

Janelle Bradley
Study findings revealed that 90% of patients with metastatic NSCLC in The US Oncology Network received ≥1 biomarker test prior to first-line treatment, though
Study findings revealed that 90% of patients with metastatic NSCLC in The US Oncology Network received ≥1 biomarker test prior to first-line treatment, though
Study findings revealed that 90%...
04/01/2022
Journal of Clinical Pathways

Advertisement

News
Ensartinib vs Crizotinib for ALK-Positive NSCLC
09/16/2021
Ensartinib demonstrated superior efficacy to crizotinib for patients with advanced ALK-positive NSCLC in a study published in JAMA Oncology.
Ensartinib demonstrated superior efficacy to crizotinib for patients with advanced ALK-positive NSCLC in a study published in JAMA Oncology.
Ensartinib demonstrated superior...
09/16/2021
Journal of Clinical Pathways
News
National Quality Measure Compliance for Palliative Bone Radiation in NSCLC
09/01/2021
Findings from a recent study suggest that compliance with the National Quality Forum’s measure 1822 have increased over time among patients treated for metastatic non–small cell lung cancer.
Findings from a recent study suggest that compliance with the National Quality Forum’s measure 1822 have increased over time among patients treated for metastatic non–small cell lung cancer.
Findings from a recent study...
09/01/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use